Risperdal (risperidone) is a prescription antipsychotic medication, which is approved by the Food & Drug Administration (FDA) for treatment of schizophrenia, bipolar disorder, and irritability related to autism. For a long time, pediatric doctors routinely prescribed Risperdal "off-label" for children and adolescents. While licensed doctors are always free to prescribe a drug for any use they see fit, lawsuits against the maker of Risperdal (Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson), have alleged that the company improperly promoted the drug for use in children and adolescents.
Those lawsuits also claim that Risperdal poses a serious risk of gynecomastia (development of breast growth), and that the drug caused the condition in young boys and adolescent young men exposed to the drug. Cases have been filed in various courts across the country, including the Philadelphia Court of Common Pleas, which is home to nearly 7,000 personal injury product liability cases involving Risperdal and claims of gynecomastia. On October 8, 2019, in the case of Murray v. Janssen, a Philadelphia jury brought back a punitive damages verdict of $8 billion dollars. Leckman Law and its joint venture, Littlepage Booth Leckman, represent several plaintiffs in the litigation and continue to investigate claims. If you or a loved one believe you have a claim, or if you are an attorney seeking assistance in the work-up or trial of a Risperdal case in Philadelphia, contact us immediately for a free evaluation of your case.